MedPath

T-Balance Therapeutics GmbH

🇩🇪Germany
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:1
Completed:1

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients

Phase 2
Completed
Conditions
Allergy to House Dust Mite
Allergic Asthma
Interventions
Other: Placebo
First Posted Date
2020-12-17
Last Posted Date
2022-02-08
Lead Sponsor
T-Balance Therapeutics GmbH
Target Recruit Count
42
Registration Number
NCT04673591
Locations
🇩🇪

Medaimun GmbH, Frankfurt, Germany

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.